Discussion and conclusions
CSH is a rare disorder diagnosed only on the basis of pathologic features, but its prominent association with lymphoproliferative disorders has been expounded in the literature. To date, 140 cases of CSH have been reported according to a PubMed search of the English literature. Patients can be classified into localized CSH (L-CSH) and generalized CSH (G-CSH) based on the number of the foci. G-CSH, which entails the involvement of two or more organs/systems, may present with a rapid clinical course and portend a worse prognosis [
2]. Recently, Fang H et al. reported 8 cases of CSH with bone marrow involvement and reviewed the English literature (total of 131 cases) from 1987 to 2017 [
3]. Of the 131 cases of CSH, 100 cases (76%) were associated with a lymphoproliferative disorder, mainly MM, LPL, and MGUS. Thirty-five cases (27%) were accompanied with B-cell lymphoma, but none of these lymphomas were aggressive B-cell lymphoma. To the best of our knowledge, this is the first case of CSH with DLBCL.
DLBCL was mentioned in 5 patients with CSH in the literature (Table
1), and four of these cases transformed from or were accompanied with low-grade B-cell lymphoma [
4‐
7]. Although a concurrent low-grade B-cell component cannot be completely excluded in the unbiopsied sites of abdominal lymphadenopathy in the present case, biopsies of multiple anatomic sites failed to obtain any evidence of low-grade B-cell lymphoma, and normal bone marrow biopsy and the undetected
MYD88 mutation contributed to the exclusion of LPL. In addition, there was no history of lymphoproliferative disorders in our patient. Kawano et al. reported a case of pulmonary L-CSH without lymphoproliferative disorders in a patient with a history of gastric DLBCL [
8]. In that report, the gastric DLBCL retained CR without evidence of recurrence, and the PCR analysis with stomach and lung tissues did not reveal the same clone. Thus, the ultimate diagnosis was L-CSH without lymphoproliferative disorders. Similarly, in the present case, the CSH lesions and the DLBCL involved different anatomic sites respectively and exhibited unrelated Ig
H gene monoclonal peaks in PCR analysis. However, the presence of MG and the generalized CSH raised concerns for a systematic association. As expected, subsequent immunohistochemistry showed strong IgM staining in some DLBCL cells without plasmablastic differentiation. These neoplasm cells may be responsible for the IgM type of MG and the generalized CSH. In addition, the level of serum paraprotein changed with the response to chemotherapy, and this finding could point to the unusual origin of immunoglobulins. Taking these findings together, we preferred a diagnosis of CSH with DLBCL rather than a CSH independent of the DLBCL and MG.
Table 1
Summary of CSH cases coexistent with DLBCL
| 61/F | Subcutaneous masses | G-CSH with LPL in transformation to a large cell lymphoma | IgM kappa IgG lambda | Skin, LN | Not reported |
| 70/M | Splenomegaly | G-CSH with LPL | IgM kappa | BM, LN | Transformed to DLBCL at 24mos |
| 77/F | Bilateral cervical lymphadenopathy | G-CSH with Low-grade monocytoid B-cell lymphoma | lambda | Parotid and submandibular glands, LN | Transformed to DLBCL at 8ys |
| 80/F | Bilateral periorbital swelling | L-CSH with WM | IgM kappa | Skin | Transformed to DLBCL at 6ys and died of disease |
| 80/M | Asymptomatic/ Gastric DLBCL 13 years ago(CR) | L-CSH without LP-PCD | None | Lung | Live free of disease at a 23mos follow-up |
Present case | 74/F | Abdominal pain, fever, subcutaneous masses | G-CSH with DLBCL | IgM kappa | Soft tissue, LN | Live with disease at a 1y follow-up |
The mechanism of crystal formation is unclear. It is hypothesized that a combination of overproduction and conformational alterations in the immunoglobin light chains leads to crystallization, impaired enzymatic degradation by histiocytes, and crystal accumulation within histiocytes [
9‐
11]. Afterwards, Kanagal-Shamanna et al. observed that the sole representation of the variable region of immunoglobin heavy chains contributed to abnormal immunoglobin structure by proteomic methods, expanding the proposed hypothesis [
12]. The present case posed a diagnostic challenge due to the separate locations of the CSH and DLBCL, and gene-rearrangement studies showed that the variable region encoded by Ig
H-DH-JH gene segments may be related to the crystallization. More molecular analyses are required to clarify the mechanism.
It is morphologically difficult to distinct CSH from other histiocytosis and sedimentary lesions, such as xanthogranuloma, Langerhans cell histiocytosis, granular cell tumour, fibrous histiocytoma, amyloidosis, and Gaucher’s disease. On low-power images, CSH is characterized by sheets of polygonal or spindle-shaped histiocytes with abundant eosinophilic cytoplasm. On high-power images, refractive needle-like crystalline material filled the cytoplasm. Immunohistochemical analysis is useful to the differential diagnosis. In our case, CD68 and CD163 immunohistochemical stains confirmed that the large, pink cells were histiocytes. S100 protein immunohistochemical stain excluded the possibility of granular cell tumour and Langerhans cell histiocytosis. Congo red excluded amyloidosis, and desmin, MSA and myogenin were performed to exclude adult rhabdomyoma. There were a few cases of CSH mimicking adult rhabdomyoma given the similar morphologic features and location in soft tissue [
13‐
15]. In patients with a malignant tumour, CSH may be clinically diagnosed as metastatic carcinoma [
16].
Finally, the treatment and prognosis of patients with CSH vary depending on the associated disease [
2]. Regarding DLBCL, MG was reported as a poor prognostic marker in patients with the non-GCB type [
17]. The outcome after R-CHOP was unsatisfactory in IgM-secreting DLBCL patients, while immunochemotherapy combined with bortezomib or lenalidomide seemed to be more effective [
18]. In our patient, the general status improved with R-CHOP. However, the serum paraprotein remained elevated, and multiple lymph node involvement remained detectable. Lenalidomide accelerated the disappearance of paraprotein and might play a positive role in this subset of patients. Further accumulation of cases is essential to expound the treatment and prognosis of CSH and DLBCL with MG.
In conclusion, the presented case is the first to describe G-CSH concomitant with DLBCL and MG. The rarity of CSH and separate locations of CSH and DLBCL contributed to the complexity of the diagnostic approach. This case highlights an unusual origin of immunoglobulins and the overproduction of the immunoglobulins may promote the G-CSH. Immunohistochemical analysis can assist in differential diagnosis and classification. Once a pathologic diagnosis of CSH is confirmed, subsequent investigations for the underlying lymphoproliferative disorders are required, such as a detailed clinical history, serum and urine protein studies, imaging examinations and bone marrow biopsy.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.